However, not all CHB patients are candidates for NA treatment, which is initiated based on predictors of disease progression, such as elevated alanine transaminase (ALT), elevated HBV DNA, development of fibrosis/cirrhosis, immunosuppression, family history of HCC, or pregnancy with HBV DNA above 200,000 IU/mL [6]. This evidence concerns the gene GPT and Cirrhosis.